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Today, nearly twenty-five years since the first AIDS cases
were identified, the AIDS pandemic is recognized as a glo-
bal public health priority. With 14,000 new HIV infec-
tions every day, the best hope for stemming the insidious
spread of HIV and for ending the pandemic remains the
development of a safe and effective AIDS vaccine. The
search for an AIDS vaccine can be viewed from past,
present, and future perspectives. Since the identification
in 1983 of HIV as the etiologic cause of AIDS, the field has
gained significant knowledge on the pathogenesis of HIV
relevant for vaccine development, several vaccine
approaches have been designed and tested in clinical tri-
als, and infrastructure has been established both in devel-
oped and developing countries to assess HIV incidence,
molecular epidemiology, host immune response to early
infection, and to conduct Phase I, II and III trials. Yet
despite current global investment of nearly $650 million
per year, the HIV vaccine pipeline remains inadequate.
Vaccine candidates designed by empiric approaches and
tested thus far in human efficacy trials have failed to pre-
vent HIV infection or suppress HIV viral load. Current
candidates approaching human efficacy trials have shown
some benefit in certain monkey models but not in others.
There is considerable potential that these current candi-
dates will achieve no more than limited success if any,
since they have provided little or no protection from path-
ogenic SIV challenge in monkeys, are markedly impeded
in their capacity to elicit cell mediated immune responses
in humans due to anti-vector immunity, and have not
been designed to elicit effective neutralizing antibodies. In
order to significantly accelerate global efforts in AIDS vac-
cine development and shorten the timetable for a licensed
and widely accessible AIDS vaccine, the following issues
should be addressed. First of all, key scientific problems,
known to the field for more than a decade, need focused
and direct efforts to inform rational vaccine design. These
problems include: the lack of understanding of how best
to design vaccines to elicit broadly neutralizing antibodies
to HIV; the lack of safe and suitable candidates for clinical
development which mimic the protective efficacy thus far
only achieved by live attenuated SIV vaccines; and the lack
of candidates in the pipeline which adequately address
the hypervariability of HIV. Secondly, an "industrial
model" for applied research and product development
needs to be incorporated into global AIDS vaccine R&D
efforts, to facilitate an expedited transfer of leading vac-
cine candidates demonstrating feasibility/proof of con-
cept to major vaccine-pharmaceutical companies for
advanced development. Finally, a shift from business as
usual risk-benefit paradigms common to vaccine R&D
needs to be established to encourage innovative product
development and accelerated clinical testing of AIDS vac-
cine candidates without compromising safety.
from 2005 International Meeting of The Institute of Human Virology
Baltimore, USA, 29 August – 2 September 2005
Published: 8 December 2005
Retrovirology 2005, 2(Suppl 1):S30 doi:10.1186/1742-4690-2-S1-S30
<supplement> <title> <p>2005 International Meeting of The Institute of Human Virology</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. [link 'here' using 'a href' to: <url>http://www.biomedcentral.com/content/pdf/1742-4690-2-S1-full. df</url>]</not /supplement>
